Publication:
Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactie pathogens in goats

Simple item page
dc.contributor.authorSerrano-Rodríguez, Juan Manuel
dc.contributor.authorFernández-Varón, Emilio
dc.contributor.authorCárceles Rodríguez, Carlos
dc.contributor.authorSan Andrés-Larrea, Manuel Ignacio
dc.contributor.authorRubio-Langre, Sonia
dc.contributor.authorFé Rodríguez, David Christian de la
dc.contributor.authorWaxman Dova, Samanta
dc.contributor.authorBhardwaj, Pallavi
dc.contributor.authorSidhu, Pritam Kaur
dc.contributor.authorLitterio, Nicolás Javier
dc.contributor.authorLorenzutti, Augusto Matías
dc.contributor.departmentFarmacología
dc.contributor.otherFacultad de Veterinaria
dc.date.accessioned2026-02-27T11:32:04Z
dc.date.available2026-02-27T11:32:04Z
dc.date.copyright© 2023 Elsevier Ltd.
dc.date.issued2023-04-03
dc.description.abstractMarbofloxacin is a broad-spectrum fluoroquinolone, and an extra-label use has been reported in horse, sheep and goat. However, extrapolation of dosage regimens from cattle to horse and small ruminants could lead to incorrect dosing due to pharmacokinetic differences among species, increasing the risk of antimicrobial resistance or toxicity. Pharmacokinetic properties of marbofloxacin, including PK/PD analysis, have been studied by intravenous, intramuscular and subcutaneous administration in lactating and non-lactating goats. A population pharmacokinetic model of marbofloxacin in goats was built using 10 pharmacokinetic studies after intravenous, intramuscular, and subcutaneous administration at a dose of 2, 5 and 10 mg/kg. Serum or plasma and milk concentration-time profiles were simultaneously fitted with a non-linear mixed effect model with Monolix software. Level of milk production (lactating and non-lactating) and health status (healthy and un-healthy) were retained as covariates on volume of distribution and clearance. Marbofloxacin concentrations were well described in plasma/serum and milk by the population model. Simulated dose regimens of marbofloxacin administered at 2, 5 and 10 mg/kg by intramuscular route for five days were evaluated (n = 5000 per group). Steady-state fAUCs for each dose regimen were obtained. Probability of target attainment of fAUC/MIC ratios were determined and PK/PDco values (highest MIC for which 90% of individuals can achieve a prior numerical value of the fAUC/MIC index) were established using Monte Carlo simulations (n = 50,000). MIC values for wild type isolates of Staphylococcus aureus, coagulase negative staphylococci, and Mycoplasma agalactiae were determined and tentative epidemiological cutoff (TECOFF) were obtained at 1.0, 0.5 and 0.5 mg/L, respectively. The PK/PDco for the dose regimen of 2 mg/kg/24 h and 5 mg/kg/24 h (0.125 and 0.25 mg/L) were lower than TECOFF (0.5 and 1 mg/L). The dosage regimen of 10 mg/kg/24 h was adequate for intermediate MIC values of 0.125–0.50 mg/L and could be effective for a population with a target fAUC/MIC ratio ˂ 48 for Coagulase negative staphylococci and Mycoplasma agalactiae, but not for Staphylococcus aureus. Results obtained in this study could be taken as a starting point by committees that set the clinical breakpoints and justifies expert rules to optimize marbofloxacin dose regimens.
dc.formatapplication/pdf
dc.format.extent10
dc.identifier.citationResearch in Veterinary Science 159 (2023) 1–10
dc.identifier.doihttps://doi.org/10.1016/j.rvsc.2023.03.026
dc.identifier.eissn1532-2661
dc.identifier.issn0034-5288
dc.identifier.urihttp://hdl.handle.net/10201/215921
dc.languageeng
dc.publisherElsevier
dc.relationSin financiación externa a la Universidad
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0034528823000991
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectPopulation pharmacokinetic
dc.subjectMarbofloxacin
dc.subjectGoats Milk
dc.subjectMonte Carlo simulations
dc.subject.odsObjetivo 2: Hambre y seguridad alimentaria
dc.titlePopulation pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactie pathogens in goats
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublicationes
relation.isAuthorOfPublicationc66773e2-bfe1-46fe-9f7d-1ea3741b8376
relation.isAuthorOfPublication359ce0bd-281e-491c-9e6e-b63fb67bd903
relation.isAuthorOfPublication.latestForDiscoveryc66773e2-bfe1-46fe-9f7d-1ea3741b8376
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Population pharmacokinetics and pharmacokinetic-pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactie pathogens in goats.pdf
Size:
4.16 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos